Rethinking glomerular basement membrane thickening in diabetic nephropathy: Adaptive or pathogenic?

American Journal of Physiology - Renal Physiology

Volumn 311, Issue 5, 2016, Pages F831-F843

  Marshall, Caroline B ^a,b  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Glomerular filtration barrier; Podocyte; Podocyte glomerular basement membrane interface

Indexed keywords

COLLAGEN TYPE 17; DYSTROGLYCAN; INTEGRIN; LAMININ; MATRIX METALLOPROTEINASE; PROTEOGLYCAN; PROTEOHEPARAN SULFATE; SYNDECAN 1; SYNDECAN 4; TETRASPANIN; VERY LATE ACTIVATION ANTIGEN 3;

ALBUMINURIA; CELL SURFACE; DIABETIC NEPHROPATHY; END STAGE RENAL DISEASE; EXTRACELLULAR MATRIX; GENE DISRUPTION; GLOMERULAR FILTRATION BARRIER; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS CAPILLARY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY HYPERTROPHY; MICROALBUMINURIA; PODOCYTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVIEW; TURNOVER TIME; ANIMAL; CHRONIC KIDNEY FAILURE; GLOMERULUS; PATHOLOGY;

ANIMALS; DIABETIC NEPHROPATHIES; GLOMERULAR BASEMENT MEMBRANE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY GLOMERULUS; PODOCYTES;

EID: 84994662886     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00313.2016     Document Type: Review

References (198)

1. Abrahamson DR. Development of kidney glomerular endothelial cells and their role in basement membrane assembly. Organogenesis 5: 275-287, 2009.
2. Abrahamson DR. Glomerulogenesis in the developing kidney. Semin Nephrol 11: 375-389, 1991.
3. Abrahamson DR. Role of the podocyte (and glomerular endothelium) in building the GBM. Semin Nephrol 32: 342-349, 2012.
4. Abrahamson DR, Hudson BG, Stroganova L, Borza DB, St. John PL. Cellular origins of type IV collagen networks in developing glomeruli. J Am Soc Nephrol 20: 1471-1479, 2009.
5. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, Ukpds G. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63: 225-232, 2003.
6. Adler S. Characterization of glomerular epithelial cell matrix receptors. Am J Pathol 141: 571-578, 1992.
7. Adler S. Structure-function relationships associated with extracellular matrix alterations in diabetic glomerulopathy. J Am Soc Nephrol 5:1165-1172, 1994.
8. Akuffo EL, Hunt JR, Moss J, Woodrow D, Davies M, Mason RM. A steady-state labelling approach to the measurement of proteoglycan turnover in vivo and its application to glomerular proteoglycans. Biochem J 320: 301-308, 1996.
9. Anil Kumar P, Welsh GI, Saleem MA, Menon RK. Molecular and cellular events mediating glomerular podocyte dysfunction and depletion in diabetes mellitus. Front Endocrinol (Lausanne) 5:151, 2014.
10. Aumailley M, Has C, Tunggal L, Bruckner-Tuderman L. Molecular basis of inherited skin-blistering disorders, and therapeutic implications. Expert Rev Mol Med 8: 1-21, 2006.
11. Bader BL, Smyth N, Nedbal S, Miosge N, Baranowsky A, Mokkapati S, Murshed M, Nischt R. Compound genetic ablation of nidogen 1 and 2 causes basement membrane defects and perinatal lethality in mice. Mol Cell Biol 25: 6846-6856, 2005.
12. Bai Y, Wang L, Li Y, Liu S, Li J, Wang H, Huang H. High ambient glucose levels modulates the production of MMP-9 and alpha5(IV) collagen by cultured podocytes. Cell Physiol Biochem 17: 57-68, 2006.
13. Baleato RM, Guthrie PL, Gubler MC, Ashman LK, Roselli S. Deletion of CD151 results in a strain-dependent glomerular disease due to severe alterations of the glomerular basement membrane. Am J Pathol 173: 927-937, 2008.
14. Baraldi A, Furci L, Zambruno G, Rubbiani E, Annessi G, Lusvarghi E. Very late activation-3 integrin is the dominant beta 1-integrin on the glomerular capillary wall: an immunofluorescence study in nephrotic syndrome. Nephron 62: 382-388, 1992.
15. Baraldi A, Zambruno G, Furci L, Manca V, Vaschieri C, Lusvarghi E. Beta-1 integrins in the normal human glomerular capillary wall: an immunoelectron microscopy study. Nephron 66: 295-301, 1994.
16. Basu R, Lee J, Wang Z, Patel VB, Fan D, Das SK, Liu GC, John R, Scholey JW, Oudit GY, Kassiri Z. Loss of TIMP3 selectively exacerbates diabetic nephropathy. Am J Physiol Renal Physiol 303:F1341-F1352, 2012.
17. Beavan LA, Davies M, Couchman JR, Williams MA, Mason RM. In vivo turnover of the basement membrane and other heparan sulfate proteoglycans of rat glomerulus. Arch Biochem Biophys 269: 576-585, 1989.
18. Bendayan M. Alteration in the distribution of type IV collagen in glomerular basal laminae in diabetic rats as revealed by immunocytochemistry and morphometrical approach. Diabetologia 28: 373-378, 1985.
19. Berditchevski F. Complexes of tetraspanins with integrins: more than meets the eye. J Cell Sci 114: 4143-4151, 2001.
20. Bertolatus JA, Hunsicker LG. Polycation binding to glomerular basement membrane. Effect of biochemical modification. Lab Invest 56:170-179, 1987.
21. Bjornson Granqvist A, Ebefors K, Saleem MA, Mathieson PW, Haraldsson B, Nystrom JS. Podocyte proteoglycan synthesis is involved in the development of nephrotic syndrome. Am J Physiol Renal Physiol 291:F722-F730, 2006.
22. Bohrer MP, Baylis C, Humes HD, Glassock RJ, Robertson CR, Brenner BM. Permselectivity of the glomerular capillary wall. Facilitated filtration of circulating polycations. J Clin Invest 61: 72-78, 1978.
23. Brown DM, Klein DJ, Michael AF, Oegema TR. 35S-glycosaminoglycan and 35S-glycopeptide metabolism by diabetic glomeruli and aorta. Diabetes 31: 418-425, 1982.
24. Brownlee M, Spiro RG. Glomerular basement membrane metabolism in the diabetic rat. In vivo studies. Diabetes 28: 121-125, 1979.
25. Byron A, Randles MJ, Humphries JD, Mironov A, Hamidi H, Harris S, Mathieson PW, Saleem MA, Satchell SC, Zent R, Humphries MJ, Lennon R. Glomerular cell cross-talk influences composition and assembly of extracellular matrix. J Am Soc Nephrol 25: 953-966, 2014.
26. Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes 52: 1036-1040, 2003.
27. Caramori ML, Kim Y, Huang C, Fish AJ, Rich SS, Miller ME, Russell G, Mauer M. Cellular basis of diabetic nephropathy. 1. Study design and renal structural-functional relationships in patients with longstanding type 1 diabetes. Diabetes 51: 506-513, 2002.
28. Caramori ML, Parks A, Mauer M. Renal lesions predict progression of diabetic nephropathy in type 1 diabetes. J Am Soc Nephrol 24: 1175-1181, 2013.
29. Catania JM, Chen G, Parrish AR. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 292:F905-F911, 2007.
30. Cevikbas F, Schaefer L, Uhlig P, Robenek H, Theilmeier G, Echtermeyer F, Bruckner P. Unilateral nephrectomy leads to up-regulation of syndecan-2- and TGF-beta-mediated glomerulosclerosis in syndecan-4 deficient male mice. Matrix Biol 27: 42-52, 2008.
31. Chan FL, Inoue S, Leblond CP. The basement membranes of cryofixed or aldehyde-fixed, freeze-substituted tissues are composed of a lamina densa and do not contain a lamina lucida. Cell Tissue Res 273: 41-52, 1993.
32. Chang RL, Deen WM, Robertson CR, Brenner BM. Permselectivity of the glomerular capillary wall. III. Restricted transport of polyanions. Kidney Int 8: 212-218, 1975.
33. Chen HC, Chen CA, Guh JY, Chang JM, Shin SJ, Lai YH. Altering expression of alpha3beta1 integrin on podocytes of human and rats with diabetes. Life Sci 67: 2345-2353, 2000.
34. Chen S, Wassenhove-McCarthy D, Yamaguchi Y, Holzman L, van Kuppevelt TH, Orr AW, Funk S, Woods A, McCarthy K. Podocytes require the engagement of cell surface heparan sulfate proteoglycans for adhesion to extracellular matrices. Kidney Int 78: 1088-1099, 2010.
35. Chen S, Wassenhove-McCarthy DJ, Yamaguchi Y, Holzman LB, van Kuppevelt TH, Jenniskens GJ, Wijnhoven TJ, Woods AC, McCarthy KJ. Loss of heparan sulfate glycosaminoglycan assembly in podocytes does not lead to proteinuria. Kidney Int 74: 289-299, 2008.
36. Cheng H, Harris RC. The glomerulus-a view from the outside-the podocyte. Int J Biochem Cell Biol 42: 1380-1387, 2010.
37. Cohen MP, Klein CV. Glomerulopathy in rats with streptozotocin diabetes. Accumulation of glomerular basement membrane analogous to human diabetic nephropathy. J Exp Med 149: 623-631, 1979.
38. Cohen MP, Klepser H, Wu VY. Undersulfation of glomerular basement membrane heparan sulfate in experimental diabetes and lack of correction with aldose reductase inhibition. Diabetes 37: 1324-1327, 1988.
39. Cohen MP, Surma ML. [(35)S]sulfate incorporation into glomerular basement membrane glycosaminoglycans is decreased in experimental diabetes. J Lab Clin Med 98: 715-722, 1981.
40. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, Kasiske B, Kutner N, Liu J, St Peter W, Guo H, Gustafson S, Heubner B, Lamb K, Li S, Li S, Peng Y, Qiu Y, Roberts T, Skeans M, Snyder J, Solid C, Thompson B, Wang C, Weinhandl E, Zaun D, Arko C, Chen SC, Daniels F, Ebben J, Frazier E, Hanzlik C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, Everson S, Eggers P, Agodoa L. United States Renal Data System 2011 Annual Data Report:Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis 59: A7, e1-e420, 2012.
41. Cusumano AM, Bodkin NL, Hansen BC, Iotti R, Owens J, Klotman PE, Kopp JB. Glomerular hypertrophy is associated with hyperinsulinemia and precedes overt diabetes in aging rhesus monkeys. Am J Kidney Dis 40: 1075-1085, 2002.
42. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. J Am Med Assoc 305: 2532-2539, 2011.
43. Del Prete D, Anglani F, Forino M, Ceol M, Fioretto P, Nosadini R, Baggio B, Gambaro G. Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM. Diabetologia 40: 1449-1454, 1997.
44. Desjardins M, Bendayan M. Ultrastructural distribution of glomerular basement membrane components in experimental diabetes. Diabetes Res 14: 65-73, 1990.
45. Diamant M, Hanemaaijer R, Verheijen JH, Smit JW, Radder JK, Lemkes HH. Elevated matrix metalloproteinase-2 and -9 in urine, but not in serum, are markers of type 1 diabetic nephropathy. Diabet Med 18:423-424, 2001.
46. Diez-Sampedro A, Lenz O, Fornoni A. Podocytopathy in diabetes: a metabolic and endocrine disorder. Am J Kidney Dis 58: 637-646, 2011.
47. Digtyar AV, Pozdnyakova NV, Feldman NB, Lutsenko SV, Severin SE. Endostatin: current concepts about its biological role and mechanisms of action. Biochemistry (Mosc) 72: 235-246, 2007.
48. Ewens KG, George RA, Sharma K, Ziyadeh FN, Spielman RS. Assessment of 115 candidate genes for diabetic nephropathy by transmission/ disequilibrium test. Diabetes 54: 3305-3318, 2005.
49. Farquhar MG. The glomerular basement membrane: not gone, just forgotten. J Clin Invest 116: 2090-2093, 2006.
50. Farquhar MG, Hopper J Jr, Moon HD. Diabetic glomerulosclerosis:electron and light microscopic studies. Am J Pathol 35: 721-753, 1959.
51. Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 486: 247-251, 2000.
52. Fiorentino L, Cavalera M, Menini S, Marchetti V, Mavilio M, Fabrizi M, Conserva F, Casagrande V, Menghini R, Pontrelli P, Arisi I, D’Onofrio M, Lauro D, Khokha R, Accili D, Pugliese G, Gesualdo L, Lauro R, Federici M. Loss of TIMP3 underlies diabetic nephropathy via FoxO1/STAT1 interplay. EMBO Mol Med 5: 441-455, 2013.
53. Fioretto P, Steffes MW, Mauer M. Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes 43:1358-1364, 1994.
54. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev 93: 137-188, 2013.
55. Franzke CW, Tasanen K, Schumann H, Bruckner-Tuderman L. Collagenous transmembrane proteins: collagen XVII as a prototype. Matrix Biol 22: 299-309, 2003.
56. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358: 580-591, 2008.
57. Goldberg S, Harvey SJ, Cunningham J, Tryggvason K, Miner JH. Glomerular filtration is normal in the absence of both agrin and perlecanheparan sulfate from the glomerular basement membrane. Nephrol Dial Transplant 24: 2044-2051, 2009.
58. Greka A, Mundel P. Cell biology and pathology of podocytes. Ann Rev Physiol 74: 299-323, 2012.
59. Groffen AJ, Ruegg MA, Dijkman H, van de Velden TJ, Buskens CA, van den Born J, Assmann KJ, Monnens LA, Veerkamp JH, van den Heuvel LP. Agrin is a major heparan sulfate proteoglycan in the human glomerular basement membrane. J Histochem Cytochem 46: 19-27, 1998.
60. Groffen AJ, Veerkamp JH, Monnens LA, van den Heuvel LP. Recent insights into the structure and functions of heparan sulfate proteoglycans in the human glomerular basement membrane. Nephrol Dial Transplant 14: 2119-2129, 1999.
61. Gubler MC. Inherited diseases of the glomerular basement membrane. Nat Clin Pract Nephrol 4: 24-37, 2008.
62. Guo L, Sanders PW, Woods A, Wu C. The distribution and regulation of integrin-linked kinase in normal and diabetic kidneys. Am J Pathol 159: 1735-1742, 2001.
63. Han SY, Jee YH, Han KH, Kang YS, Kim HK, Han JY, Kim YS, Cha DR. An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy. Nephrol Dial Transplant 21: 2406-2416, 2006.
64. Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 88: 451-487, 2008.
65. Harvey SJ, Jarad G, Cunningham J, Rops AL, van der Vlag J, Berden JH, Moeller MJ, Holzman LB, Burgess RW, Miner JH. Disruption of glomerular basement membrane charge through podocytespecific mutation of agrin does not alter glomerular permselectivity. Am J Pathol 171: 139-152, 2007.
66. Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 6: 801-811, 2005.
67. Hironaka K, Makino H, Yamasaki Y, Ota Z. Pores in the glomerular basement membrane revealed by ultrahigh-resolution scanning electron microscopy. Nephron 64: 647-649, 1993.
68. Hoorn EJ, Taams NE, Hurskainen T, Salih M, Weening JJ, Jonkman MF, Pas HH, Schreurs MW. Bullous Pemphigoid With a Dual Pattern of Glomerular Immune Complex Disease. Am J Kidney Dis 67:302-306, 2016.
69. Hurskainen T, Moilanen J, Sormunen R, Franzke CW, Soininen R, Loeffek S, Huilaja L, Nuutinen M, Bruckner-Tuderman L, Autio-Harmainen H, Tasanen K. Transmembrane collagen XVII is a novel component of the glomerular filtration barrier. Cell Tissue Res 348:579-588, 2012.
70. Hynes RO. The extracellular matrix: not just pretty fibrils. Science 326:1216-1219, 2009.
71. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 110: 673-687, 2002.
72. Iglesias-de la Cruz MC, Ziyadeh FN, Isono M, Kouahou M, Han DC, Kalluri R, Mundel P, Chen S. Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int 62: 901-913, 2002.
73. Inoki K, Mori H, Wang J, Suzuki T, Hong S, Yoshida S, Blattner SM, Ikenoue T, Ruegg MA, Hall MN, Kwiatkowski DJ, Rastaldi MP, Huber TB, Kretzler M, Holzman LB, Wiggins RC, Guan KL. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 121: 2181-2196, 2011.
74. Inoue S, Bendayan M. High-resolution ultrastructural study of the rat glomerular basement membrane in aminonucleoside nephrosis. Ultrastruct Pathol 20: 409-416, 1996.
75. Jarad G, Cunningham J, Shaw AS, Miner JH. Proteinuria precedes podocyte abnormalities inLamb2-/- mice, implicating the glomerular basement membrane as an albumin barrier. J Clin Invest 116: 2272-2279, 2006.
76. Jarad G, Pippin JW, Shankland SJ, Kreidberg JA, Miner JH. Dystroglycan does not contribute significantly to kidney development or function, in health or after injury. Am J Physiol Renal Physiol 300:F811-F820, 2011.
77. Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int 74: 22-36, 2008.
78. Kanasaki K, Kanda Y, Palmsten K, Tanjore H, Lee SB, Lebleu VS, Gattone VH Jr, Kalluri R. Integrin beta1-mediated matrix assembly and signaling are critical for the normal development and function of the kidney glomerulus. Dev Biol 313: 584-593, 2008.
79. Kanwar YS. Continuum of historical controversies regarding the structural- functional relationship of the glomerular ultrafiltration unit. Am J Physiol Renal Physiol 308:F420-F424, 2015.
80. Kanwar YS, Danesh FR, Chugh SS. Contribution of proteoglycans towards the integrated functions of renal glomerular capillaries: a historical perspective. Am J Pathol 171: 9-13, 2007.
81. Kanwar YS, Rosenzweig LJ. Clogging of the glomerular basement membrane. J Cell Biol 93: 489-494, 1982.
82. Kanwar YS, Sun L, Xie P, Liu FY, Chen S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol 6:395-423, 2011.
83. Karamatic Crew V, Burton N, Kagan A, Green CA, Levene C, Flinter F, Brady RL, Daniels G, Anstee DJ. CD151, the first member of the tetraspanin (TM4) superfamily detected on erythrocytes, is essential for the correct assembly of human basement membranes in kidney and skin. Blood 104: 2217-2223, 2004.
84. Kassiri Z, Oudit GY, Kandalam V, Awad A, Wang X, Ziou X, Maeda N, Herzenberg AM, Scholey JW. Loss of TIMP3 enhances interstitial nephritis and fibrosis. J Am Soc Nephrol 20: 1223-1235, 2009.
85. Kemeny E, Mihatsch MJ, Durmuller U, Gudat F. Podocytes loose their adhesive phenotype in focal segmental glomerulosclerosis. Clin Nephrol 43: 71-83, 1995.
86. Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, Kim KW, Lee ST, Kwon YG. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 60: 5410-5413, 2000.
87. Kinnunen AI, Sormunen R, Elamaa H, Seppinen L, Miller RT, Ninomiya Y, Janmey PA, Pihlajaniemi T. Lack of collagen XVIII long isoforms affects kidney podocytes, whereas the short form is needed in the proximal tubular basement membrane. J Biol Chem 286: 7755-7764, 2011.
88. Korhonen M, Ylanne J, Laitinen L, Cooper HM, Quaranta V, Virtanen I. Distribution of the alpha 1-alpha 6 integrin subunits in human developing and term placenta. Lab Invest 65: 347-356, 1991.
89. Korhonen M, Ylanne J, Laitinen L, Virtanen I. Distribution of beta 1 and beta 3 integrins in human fetal and adult kidney. Lab Invest 62:616-625, 1990.
90. Kreidberg JA, Donovan MJ, Goldstein SL, Rennke H, Shepherd K, Jones RC, Jaenisch R. Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis. Development 122: 3537-3547, 1996.
91. Kriz W, Shirato I, Nagata M, LeHir M, Lemley KV. The podocyte’s response to stress: the enigma of foot process effacement. Am J Physiol Renal Physiol 304:F333-F347, 2013.
92. Kubosawa H, Kondo Y. Ultrastructural organization of the glomerular basement membrane as revealed by a deep-etch replica method. Cell Tissue Res 242: 33-39, 1985.
93. Lee SJ, Jang JW, Kim YM, Lee HI, Jeon JY, Kwon YG, Lee ST. Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett 519: 147-152, 2002.
94. Leeuwis JW, Nguyen TQ, Dendooven A, Kok RJ, Goldschmeding R. Targeting podocyte-associated diseases. Adv Drug Deliv Rev 62: 1325-1336, 2010.
95. Lennon R, Byron A, Humphries JD, Randles MJ, Carisey A, Murphy S, Knight D, Brenchley PE, Zent R, Humphries MJ. Global analysis reveals the complexity of the human glomerular extracellular matrix. J Am Soc Nephrol 25: 939-951, 2014.
96. Lennon R, Randles MJ, Humphries MJ. The importance of podocyte adhesion for a healthy glomerulus. Front Endocrinol (Lausanne) 5:160, 2014.
97. Li SY, Huang PH, Yang AH, Tarng DC, Yang WC, Lin CC, Chen JW, Schmid-Schonbein G, Lin SJ. Matrix metalloproteinase-9 deficiency attenuates diabetic nephropathy by modulation of podocyte functions and dedifferentiation. Kidney Int 86: 358-369, 2014.
98. Liu G, Clement LC, Kanwar YS, Avila-Casado C, Chugh SS. ZHX proteins regulate podocyte gene expression during the development of nephrotic syndrome. J Biol Chem 281: 39681-39692, 2006.
99. Mac-Moune Lai F, Szeto CC, Choi PC, Ho KK, Tang NL, Chow KM, Li PK, To KF. Isolate diffuse thickening of glomerular capillary basement membrane: a renal lesion in prediabetes? Mod Pathol 17: 1506-1512, 2004.
100. Mariappan MM. Signaling mechanisms in the regulation of renal matrix metabolism in diabetes. Exp Diabetes Res 2012:749812, 2012.
101. Marshall CB, Shankland SJ. Cell cycle regulatory proteins in podocyte health and disease. Nephron Exp Nephrol 106:e51-e59, 2007.
102. Marshall SM. The podocyte: a potential therapeutic target in diabetic nephropathy? Curr Pharm Des 13: 2713-2720, 2007.
103. Matejas V, Hinkes B, Alkandari F, Al-Gazali L, Annexstad E, Aytac MB, Barrow M, Blahova K, Bockenhauer D, Cheong HI, Maruniak-Chudek I, Cochat P, Dotsch J, Gajjar P, Hennekam RC, Janssen F, Kagan M, Kariminejad A, Kemper MJ, Koenig J, Kogan J, Kroes HY, Kuwertz-Broking E, Lewanda AF, Medeira A, Muscheites J, Niaudet P, Pierson M, Saggar A, Seaver L, Suri M, Tsygin A, Wuhl E, Zurowska A, Uebe S, Hildebrandt F, Antignac C, Zenker M. Mutations in the human laminin beta2 (LAMB2) gene and the associated phenotypic spectrum. Hum Mutat 31: 992-1002, 2010.
104. Mauer SM, Brown DM, Matas AJ, Steffes MW. Effects of pancreatic islet transplantation on the increased urinary albumin excretion rates in intact and uninephrectomized rats with diabetes mellitus. Diabetes 27:959-964, 1978.
105. Mauer SM, Steffes MW, Brown DM. The kidney in diabetes. Am J Med 70: 603-612, 1981.
106. McAdams AJ. Glomerular capillary wall basement membrane really does have laminae lucidae: A defense. Pediatr Dev Pathol 2: 260-263, 1999.
107. McCarthy KJ. Morphogenesis of the glomerular filter: the synchronous assembly and maturation of two distinct extracellular matrices. Microsc Res Tech 39: 233-253, 1997.
108. McCarthy KJ, Wassenhove-McCarthy DJ. The glomerular basement membrane as a model system to study the bioactivity of heparan sulfate glycosaminoglycans. Microsc Microanal 18: 3-21, 2012.
109. Mihai S, Sitaru C. Immunopathology and molecular diagnosis of autoimmune bullous diseases. J Cell Mol Med 11: 462-481, 2007.
110. Miner JH. The glomerular basement membrane. Exp Cell Res 318:973-978, 2012.
111. Miner JH. Glomerular filtration: the charge debate charges ahead. Kidney Int 74: 259-261, 2008.
112. Miner JH. Organogenesis of the kidney glomerulus: focus on the glomerular basement membrane. Organogenesis 7: 75-82, 2011.
113. Miner JH. Renal basement membrane components. Kidney Int 56:2016-2024, 1999.
114. Miner JH, Li C. Defective glomerulogenesis in the absence of laminin alpha5 demonstrates a developmental role for the kidney glomerular basement membrane. Dev Biol 217: 278-289, 2000.
115. Miosge N, Simniok T, Sprysch P, Herken R. The collagen type XVIII endostatin domain is co-localized with perlecan in basement membranes in vivo. J Histochem Cytochem 51: 285-296, 2003.
116. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14: 2534-2543, 2003.
117. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310: 356-360, 1984.
118. Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia 42: 263-285, 1999.
119. Moller CC, Pollak MR, Reiser J. The genetic basis of human glomerular disease. Adv Chronic Kidney Dis 13: 166-173, 2006.
120. Mora-Fernandez C, Dominguez-Pimentel V, de Fuentes MM, Gorriz JL, Martinez-Castelao A, Navarro-Gonzalez JF. Diabetic kidney disease: from physiology to therapeutics. J Physiol 592: 3997-4012, 2014.
121. Morita H, Yoshimura A, Kimata K. The role of heparan sulfate in the glomerular basement membrane. Kidney Int 73: 247-248, 2008.
122. Mott JD, Khalifah RG, Nagase H, Shield CF, 3rd Hudson JK, Hudson BG. Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int 52: 1302-1312, 1997.
123. Murshed M, Smyth N, Miosge N, Karolat J, Krieg T, Paulsson M, Nischt R. The absence of nidogen 1 does not affect murine basement membrane formation. Mol Cell Biol 20: 7007-7012, 2000.
124. Najafian B, Mauer M. Morphologic features of declining renal function in type 1 diabetes. Semin Nephrol 32: 415-422, 2012.
125. Nakamura T, Ushiyama C, Shimada N, Sekizuka K, Ebihara I, Hara M, Koide H. Effect of the antiplatelet drug dilazep dihydrochloride on urinary podocytes in patients in the early stage of diabetic nephropathy. Diabetes Care 23: 1168-1171, 2000.
126. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, Koide H. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 15: 1379-1383, 2000.
127. Nerlich A, Schleicher E. Immunohistochemical localization of extracellular matrix components in human diabetic glomerular lesions. Am J Pathol 139: 889-899, 1991.
128. Nicolaou N, Margadant C, Kevelam SH, Lilien MR, Oosterveld MJ, Kreft M, van Eerde AM, Pfundt R, Terhal PA, van der Zwaag B, Nikkels PG, Sachs N, Goldschmeding R, Knoers NV, Renkema KY, Sonnenberg A. Gain of glycosylation in integrin alpha3 causes lung disease and nephrotic syndrome. J Clin Invest 122: 4375-4387, 2012.
129. Noakes PG, Miner JH, Gautam M, Cunningham JM, Sanes JR, Merlie JP. The renal glomerulus of mice lacking s-laminin/laminin beta 2: nephrosis despite molecular compensation by laminin beta 1. Nat Genet 10: 400-406, 1995.
130. Nyberg P, Heikkila P, Sorsa T, Luostarinen J, Heljasvaara R, Stenman UH, Pihlajaniemi T, Salo T. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J Biol Chem 278: 22404-22411, 2003.
131. O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
132. Osterby R, Gundersen HJ. Glomerular size and structure in diabetes mellitus. I. Early abnormalities. Diabetologia 11: 225-229, 1975.
133. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99:342-348, 1997.
134. Parthasarathy N, Spiro RG. Effect of diabetes on the glycosaminoglycan component of the human glomerular basement membrane. Diabetes 31: 738-741, 1982.
135. Patari A, Forsblom C, Havana M, Taipale H, Groop PH, Holthofer H. Nephrinuria in diabetic nephropathy of type 1 diabetes. Diabetes 52:2969-2974, 2003.
136. Patrakka J, Tryggvason K. Molecular make-up of the glomerular filtration barrier. Biochem Biophys Res Commun 396: 164-169, 2010.
137. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 83: 253-307, 2003.
138. Perrin NE, Torbjornsdotter TB, Jaremko GA, Berg UB. The course of diabetic glomerulopathy in patients with type I diabetes: a 6-year follow-up with serial biopsies. Kidney Int 69: 699-705, 2006.
139. Petermann AT, Pippin J, Krofft R, Blonski M, Griffin S, Durvasula R, Shankland SJ. Viable podocytes detach in experimental diabetic nephropathy: potential mechanism underlying glomerulosclerosis. Nephron Exp Nephrol 98:e114-e123, 2004.
140. Pierson M, Cordier J, Hervouuet F, Rauber G. An unusual congenital and familial congenital malformative combination involving the eye and kidney. J Genet Hum 12: 184-213, 1963.
141. Plaisier E, Borradori L, Hellmark T, Wattiaux MJ, Flageul B, Mougenot B, Ronco P. Anti-glomerular basement membrane nephritis and bullous pemphigoid caused by distinct anti-alpha 3(IV)NC1 and anti-BP180 antibodies in a patient with Crohn’s disease. Am J Kidney Dis 40: 649-654, 2002.
142. Ponchiardi C, Mauer M, Najafian B. Temporal profile of diabetic nephropathy pathologic changes. Curr Diab Rep 13: 592-599, 2013.
143. Portik-Dobos V, Harris AK, Song W, Hutchinson J, Johnson MH, Imig JD, Pollock DM, Ergul A. Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes. Am J Physiol Regul Integr Comp Physiol 290:R435-R441, 2006.
144. Pozzi A, Jarad G, Moeckel GW, Coffa S, Zhang X, Gewin L, Eremina V, Hudson BG, Borza DB, Harris RC, Holzman LB, Phillips CL, Fassler R, Quaggin SE, Miner JH, Zent R. Beta1 integrin expression by podocytes is required to maintain glomerular structural integrity. Dev Biol 316: 288-301, 2008.
145. Pozzi A, Zent R. Hold tight or you’ll fall off: CD151 helps podocytes stick in high-pressure situations. J Clin Invest 122: 13-16, 2012.
146. Pozzi A, Zent R. Integrins in kidney disease. J Am Soc Nephrol 24:1034-1039, 2013.
147. Price RG, Spiro RG. Studies on the metabolism of the renal glomerular basement membrane. Turnover measurements in the rat with the use of radiolabeled amino acids. J Biol Chem 252: 8597-8602, 1977.
148. Pyke C, Kristensen P, Ostergaard PB, Oturai PS, Romer J. Proteoglycan expression in the normal rat kidney. Nephron 77: 461-470, 1997.
149. Reale E, Luciano L. The laminae rarae of the glomerular basement membrane. Their manifestation depends on the histochemical and histological techniques. Contrib Nephrol 80: 32-40, 1990.
150. Reeves WH, Kanwar YS, Farquhar MG. Assembly of the glomerular filtration surface. Differentiation of anionic sites in glomerular capillaries of newborn rat kidney. J Cell Biol 85: 735-753, 1980.
151. Regoli M, Bendayan M. Alterations in the expression of the alpha 3 beta 1 integrin in certain membrane domains of the glomerular epithelial cells (podocytes) in diabetes mellitus. Diabetologia 40: 15-22, 1997.
152. Ross EA, Ahmed AR. Bullous pemphigoid-associated nephropathy:report of two cases and review of the literature. Am J Kidney Dis 14:225-229, 1989.
153. Sachs N, Claessen N, Aten J, Kreft M, Teske GJ, Koeman A, Zuurbier CJ, Janssen H, Sonnenberg A. Blood pressure influences end-stage renal disease of Cd151 knockout mice. J Clin Invest 122:348-358, 2012.
154. Sachs N, Kreft M, van den Bergh Weerman MA, Beynon AJ, Peters TA, Weening JJ, Sonnenberg A. Kidney failure in mice lacking the tetraspanin CD151. J Cell Biol 175: 33-39, 2006.
155. Sachs N, Sonnenberg A. Cell-matrix adhesion of podocytes in physiology and disease. Nat Rev Nephrol 9: 200-210, 2013.
156. Sasaki T, Fukai N, Mann K, Gohring W, Olsen BR, Timpl R. Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J 17: 4249-4256, 1998.
157. Schymeinsky J, Nedbal S, Miosge N, Poschl E, Rao C, Beier DR, Skarnes WC, Timpl R, Bader BL. Gene structure and functional analysis of the mouse nidogen-2 gene: nidogen-2 is not essential for basement membrane formation in mice. Mol Cell Biol 22: 6820-6830, 2002.
158. Seppinen L, Pihlajaniemi T. The multiple functions of collagen XVIII in development and disease. Matrix Biol 30: 83-92, 2011.
159. Smithies O. Why the kidney glomerulus does not clog: a gel permeation/ diffusion hypothesis of renal function. Proc Natl Acad Sci USA 100:4108-4113, 2003.
160. St. John PL, Abrahamson DR. Glomerular endothelial cells and podocytes jointly synthesize laminin-1 and -11 chains. Kidney Int 60: 1037-1046, 2001.
161. Steffes MW, Schmidt D, McCrery R, Basgen JM, International Diabetic Nephropathy Study Group. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int 59: 2104-2113, 2001.
162. Sterk LM, de Melker AA, Kramer D, Kuikman I, Chand A, Claessen N, Weening JJ, Sonnenberg A. Glomerular extracellular matrix components and integrins. Cell Adhes Commun 5: 177-192, 1998.
163. Sterk LM, Geuijen CA, van den Berg JG, Claessen N, Weening JJ, Sonnenberg A. Association of the tetraspanin CD151 with the lamininbinding integrins alpha3beta1, alpha6beta1, alpha6beta4 and alpha7beta1 in cells in culture and in vivo. J Cell Sci 115: 1161-1173, 2002.
164. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17: 463-516, 2001.
165. Stieger N, Worthmann K, Schiffer M. The role of metabolic and haemodynamic factors in podocyte injury in diabetes. Diabetes Metab Res Rev 27: 207-215, 2011.
166. Stitt-Cavanagh E, MacLeod L, Kennedy C. The podocyte in diabetic kidney disease. Sci World J 9: 1127-1139, 2009.
167. Sugar T, Wassenhove-McCarthy DJ, Orr AW, Green J, van Kuppevelt TH, McCarthy KJ. N-sulfation of heparan sulfate is critical for syndecan-4 mediated podocyte cell-matrix interactions. Am J Physiol Renal Physiol 310:F1123-F1135, 2016.
168. Suh JH, Miner JH. The glomerular basement membrane as a barrier to albumin. Nat Rev Nephrol 9: 470-477, 2013.
169. Suleiman H, Zhang L, Roth R, Heuser JE, Miner JH, Shaw AS, Dani A. Nanoscale protein architecture of the kidney glomerular basement membrane. Elife 2:e01149, 2013.
170. Sun SZ, Wang Y, Li Q, Tian YJ, Liu MH, Yu YH. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats. Chin Med J (Engl) 119: 814-821, 2006.
171. Susztak K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55: 225-233, 2006.
172. Sward P, Rippe B. Acute and sustained actions of hyperglycaemia on endothelial and glomerular barrier permeability. Acta Physiol (Oxf) 204:294-307, 2012.
173. Takamiya Y, Fukami K, Yamagishi S, Kaida Y, Nakayama Y, Obara N, Iwatani R, Ando R, Koike K, Matsui T, Nishino Y, Ueda S, Cooper ME, Okuda S. Experimental diabetic nephropathy is accelerated in matrix metalloproteinase-2 knockout mice. Nephrol Dial Transplant 28: 55-62, 2013.
174. Tamsma JT, van den Born J, Bruijn JA, Assmann KJ, Weening JJ, Berden JH, Wieslander J, Schrama E, Hermans J, Veerkamp JH. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia 37: 313-320, 1994.
175. Tan RJ, Liu Y. Matrix metalloproteinases in kidney homeostasis and diseases. Am J Physiol Renal Physiol 302:F1351-F1361, 2012.
176. Thrailkill KM, Bunn RC, Moreau CS, Cockrell GE, Simpson PM, Coleman HN, Frindik JP, Kemp SF, Fowlkes JL. Matrix metalloproteinase-2 dysregulation in type 1 diabetes. Diabetes Care 30: 2321-2326, 2007.
177. Thrailkill KM, Clay Bunn R, Fowlkes JL. Matrix metalloproteinases:their potential role in the pathogenesis of diabetic nephropathy. Endocrine 35: 1-10, 2009.
178. Tschesche H, Zolzer V, Triebel S, Bartsch S. The human neutrophil lipocalin supports the allosteric activation of matrix metalloproteinases. Eur J Biochem 268: 1918-1928, 2001.
179. Utriainen A, Sormunen R, Kettunen M, Carvalhaes LS, Sajanti E, Eklund L, Kauppinen R, Kitten GT, Pihlajaniemi T. Structurally altered basement membranes and hydrocephalus in a type XVIII collagen deficient mouse line. Hum Mol Genet 13: 2089-2099, 2004.
180. Van den Bergh F, Giudice GJ. BP180 (type XVII collagen) and its role in cutaneous biology and disease. Adv Dermatol 19: 37-71, 2003.
181. van den Hoven MJ, Rops AL, Vlodavsky I, Levidiotis V, Berden JH, van der Vlag J. Heparanase in glomerular diseases. Kidney Int 72:543-548, 2007.
182. van den Hoven MJ, Wijnhoven TJ, Li JP, Zcharia E, Dijkman HB, Wismans RG, Rops AL, Lensen JF, van den Heuvel LP, van Kuppevelt TH, Vlodavsky I, Berden JH, van der Vlag J. Reduction of anionic sites in the glomerular basement membrane by heparanase does not lead to proteinuria. Kidney Int 73: 278-287, 2008.
183. Vogtlander NP, Dijkman H, Bakker MA, Campbell KP, van der Vlag J, Berden JH. Localization of alpha-dystroglycan on the podocyte:from top to toe. J Histochem Cytochem 53: 1345-1353, 2005.
184. Walker F. The origin, turnover and removal of glomerular basementmembrane. J Pathol 110: 233-244, 1973.
185. Welsh GI, Hale LJ, Eremina V, Jeansson M, Maezawa Y, Lennon R, Pons DA, Owen RJ, Satchell SC, Miles MJ, Caunt CJ, McArdle CA, Pavenstadt H, Tavare JM, Herzenberg AM, Kahn CR, Mathieson PW, Quaggin SE, Saleem MA, Coward RJ. Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab 12: 329-340, 2010.
186. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D’Agati VD, Schmidt AM. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162: 1123-1137, 2003.
187. White KE, Bilous RW, Marshall SM, El Nahas M, Remuzzi G, Piras G, De Cosmo S, Viberti G. Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 51: 3083-3089, 2002.
188. Williams JM, Zhang J, North P, Lacy S, Yakes M, Dahly-Vernon A, Roman RJ. Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy. Am J Physiol Renal Physiol 300:F983-F998, 2011.
189. Woroniecka KI, Park AS, Mohtat D, Thomas DB, Pullman JM, Susztak K. Transcriptome analysis of human diabetic kidney disease. Diabetes 60: 2354-2369, 2011.
190. Wu K, Setty S, Mauer SM, Killen P, Nagase H, Michael AF, Tsilibary EC. Altered kidney matrix gene expression in early stages of experimental diabetes. Acta Anat (Basel) 158: 155-165, 1997.
191. Xu X, Xiao L, Xiao P, Yang S, Chen G, Liu F, Kanwar YS, Sun L. A glimpse of matrix metalloproteinases in diabetic nephropathy. Curr Med Chem 21: 3244-3260, 2014.
192. Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, Que I, Lowik C, Timpl R, Olsen BR. Endostatin inhibits VEGFinduced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 18: 4414-4423, 1999.
193. Yao XM, Ye SD, Chen Y, Zai ZM, Li XC, Wang YX, Chen K. Rosiglitazone protects diabetic rats against kidney injury through the suppression of renal matrix metalloproteinase-9 expression. Diabetes Obes Metab 11: 519-522, 2009.
194. Yao XM, Ye SD, Zai Z, Chen Y, Li XC, Yang GW, Wang YX, Chen K. Simvastatin protects diabetic rats against kidney injury through the suppression of renal matrix metalloproteinase-9 expression. J Endocrinol Invest 33: 292-296, 2010.
195. Yauch RL, Berditchevski F, Harler MB, Reichner J, Hemler ME. Highly stoichiometric, stable, and specific association of integrin alpha3beta1 with CD151 provides a major link to phosphatidylinositol 4-kinase, and may regulate cell migration. Mol Biol Cell 9: 2751-2765, 1998.
196. Yurchenco PD, O’Rear JJ. Basement membrane assembly. Methods Enzymol 245: 489-518, 1994.
197. Zenker M, Aigner T, Wendler O, Tralau T, Muntefering H, Fenski R, Pitz S, Schumacher V, Royer-Pokora B, Wuhl E, Cochat P, Bouvier R, Kraus C, Mark K, Madlon H, Dotsch J, Rascher W, Maruniak-Chudek I, Lennert T, Neumann LM, Reis A. Human laminin beta2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. Hum Mol Genet 13: 2625-2632, 2004.
198. Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 4: 39-45, 2008.